Functional Mitral Regurgitation Clinical Trial
— EXPLORE FMROfficial title:
Early Feasibility EXperience of Posterior Leaflet RestOration to REduce Functional Mitral Regurgitation (EXPLORE FMR)
NCT number | NCT04666467 |
Other study ID # | 202002 |
Secondary ID | |
Status | Withdrawn |
Phase | N/A |
First received | |
Last updated | |
Start date | April 1, 2021 |
Est. completion date | December 31, 2022 |
Verified date | December 2023 |
Source | Polares Medical SA |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
An early feasibility study to evaluate the safety and feasibility of the PLAR Implant and Delivery System to treat severe functional mitral regurgitation and to gather preliminary data on its performance thereby providing guidance for future clinical development. The study is a single-arm registry with the last follow-up visit at 5 years post-intervention. The study will enroll up to 10 patients at up to 4 centers in North America.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | December 31, 2022 |
Est. primary completion date | December 31, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. 18 years of age or older 2. Greater than moderate functional mitral regurgitation (Grade 3+ or higher) as confirmed by transesophageal echocardiography (TEE) within 90 days prior to study procedure 3. Patient must present with an STS Score less than 10% 4. High surgical risk for conventional mitral repair or replacement due to morphological criteria (e.g. leaflet or annulus calcifications), but operable, as assessed by the local heart team comprised of a cardiac surgeon experienced in mitral valve surgery and a cardiologist experienced in treating mitral valve disease and heart failure 5. Patient is approved by an independent Patient Eligibility Committee 6. New York Heart Association (NYHA) Functional Class III or IV 7. Patient willing to participate in study and sign the IRB/EC-approved informed consent 8. Treating physician and patient agree that patient is able to return for all required post-procedure follow-up visits 9. Women of child-bearing potential have a negative pregnancy test Exclusion Criteria: 1. Severe tricuspid regurgitation 2. Severe aortic stenosis or insufficiency 3. Severe mitral annulus calcification 4. Diseased mitral anterior leaflet such as flail / prolapse/ heavy calcification 5. Implanted vena cava filter 6. Femoral veins with severe angulation and calcification 7. Contraindication for transesophageal echocardiography (TEE) or MDCT scan 8. Active infection or endocarditis 9. Previous mitral valve surgery 10. Prior orthotopic heart transplantation 11. Pulmonary artery systolic hypertension > 70mmHg 12. Evidence of intra-cardiac, inferior vena cava (IVC) or femoral venous thrombus 13. Left ventricular ejection fraction (LVEF) < 30% 14. Implant or revision of any pacing device < 30 days prior to intervention 15. Symptomatic coronary artery disease treated < 30 days prior to study procedure 16. Myocardial infarction requiring intervention < 30 days prior to study procedure 17. Infiltrative cardiomyopathies (e.g., amyloidosis, hemochromatosis, sarcoidosis), hypertrophic or restrictive cardiomyopathies, and constrictive pericarditis 18. Active peptic ulcer or upper gastrointestinal bleeding < 90 days prior to study procedure 19. Stroke < 180 days prior to study procedure 20. Severe renal insufficiency (creatinine > 3.0 mg/dL) or patient requiring dialysis 21. Cardiogenic shock at time of enrollment 22. Hemodynamic instability requiring inotropic support or mechanical heart assistance 23. Concurrent medical condition with a life expectancy of less than 2 years 24. Pregnancy at time of enrollment 25. History of bleeding diathesis or coagulopathy or leukopenia (WBC < 3,000 mcL) or acute anemia (Hb < 9 g/dL) or thrombocytopenia (platelets < 50,000 cells mcL) 26. Known hypersensitivity or contraindication to aspirin, heparin, ticlopidine or clopidogrel, nitinol, tantalum or allergy to contrast agents that cannot be pre-medicated 27. Emergency situations 28. Severe dementia or lack of capacity due to conditions that result in either inability to provide informed consent for the trial/procedure, prevent independent lifestyle outside of a chronic care facility, or will fundamentally complicate rehabilitation from the procedure or compliance with follow-up assessments 29. Company employees or their immediate family members 30. Patient is under guardianship 31. Patient is participating in another clinical study for which follow-up is currently ongoing |
Country | Name | City | State |
---|---|---|---|
United States | Emory Midtown | Atlanta | Georgia |
Lead Sponsor | Collaborator |
---|---|
Polares Medical SA |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of all-cause mortality | Primary safety outcome | 30-days | |
Primary | Incidence of change from baseline to moderate or less mitral regurgitation (Grade 2+ or less) as evaluated by 2D TTE | Primary performance endpoint | 30-days | |
Secondary | Rate of major safety events as defined by MVARC2 definitions | Secondary safety endpoint | 30 days, at 6 and 12 months, and at 2 - 5 years | |
Secondary | Technical success rate per MVARC2 definitions | Absence of procedure mortality
Successful access, delivery and retrieval of investigation delivery system Successful deployment and correct positioning of intended implant(s) Freedom from emergency surgery/re-intervention related to device or access procedure |
Technical success is measured at exit from OR | |
Secondary | Procedure success rate per MVARC2 definitions | Device success and absence of major device or procedure-related serious adverse events as below:
Death Stroke Life-threatening bleed Major vascular complication Major cardiac structural complication Stage 2 or 3 AKI MI or coronary ischemia requiring PCI or CABG Shock, heart or respiratory failure requiring IV vasopressors, mechanical intervention or prolonged intubation Valve-related dysfunction, migration, thrombosis, or other complication requiring surgery or repeat intervention |
Procedure success is measured at 30 days post-intervention | |
Secondary | Device success rate per MVARC 2 definitions (all must be present for success) | Absence of procedure mortality or stroke
Proper placement and positioning of device Freedom from unplanned re-intervention related to device or access procedure Continued intended safety and performance of the device: No evidence of structural or functional failure No device technical failure issues/complications MR reduction to moderate or less without stenosis |
Device success is measured at 30 days, at 6 and 12 months, and at 2 - 5 years post-intervention | |
Secondary | Patient success rate per MVARC2 definitions (all must be present for success) | Device success
Patient returned to pre-procedure setting No rehospitalization or reintervention for mitral regurgitation or heart failure Functional improvement from baseline by one or more NYHA class 6MWT improvement from baseline by 50 metres or more |
Patient success is measured at 12 months post-intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02520310 -
AVJ-514 Japan Trial
|
N/A | |
Not yet recruiting |
NCT04396379 -
Epicardial Mitral Touch System for Mitral Insufficiency
|
N/A | |
Not yet recruiting |
NCT05566340 -
Treatment of Moderate FMR During AVR
|
||
Completed |
NCT01899573 -
Percutaneous Left Ventricular Reshaping to Reduce Functional Mitral Regurgitation and Improve LV Function
|
N/A | |
Terminated |
NCT04529928 -
An Initial Evaluation of the Carillon Mitral Contour System for Treatment of Atrial Function Mitral Regurgitation
|
N/A | |
Recruiting |
NCT03706833 -
Edwards PASCAL CLASP IID/IIF Pivotal Clinical Trial
|
N/A | |
Completed |
NCT00800046 -
A Study of Percutaneous Repair of Functional Mitral Regurgitation Using the Ancora Heart, Inc. AccuCinch® Ventricular Repair System - The CINCH-2 Study
|
N/A | |
Active, not recruiting |
NCT03929913 -
NHLBI DIR Transcatheter Mitral Cerclage Annuloplasty Early Feasibility Study
|
N/A | |
Active, not recruiting |
NCT05988450 -
Safety and Effectiveness Study of SQ-Kyrin TMVr System for Functional Mitral Regurgitation
|
N/A | |
Recruiting |
NCT03616678 -
VenTouch OUS Feasibility Study
|
N/A | |
Not yet recruiting |
NCT04679714 -
EXPLORE FMR: Early Feasibility Study of the PLAR Implant and Delivery System to Treat Functional Mitral Regurgitation
|
N/A | |
Active, not recruiting |
NCT02701972 -
Evaluation of Safety and Efficacy of the BACE™ Device in the Treatment of Functional Mitral Valve Regurgitation [FMR
|
N/A | |
Enrolling by invitation |
NCT04776798 -
Biomechanical Taping on Low Back Pain With Increased Foot Pronation
|
N/A | |
Enrolling by invitation |
NCT05677568 -
The CINCH-FMR Post-Market Registry: Percutaneous Repair in Functional Mitral Regurgitation
|
||
Recruiting |
NCT03433274 -
Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation
|
N/A | |
Completed |
NCT05865938 -
PASCAL vs. MitralClip for Mitral Valve Transchatheter Edge-to-Edge Repair
|
||
Terminated |
NCT03016975 -
Edwards Cardioband System ACTIVE Pivotal Clinical Trial (ACTIVE)
|
N/A | |
Completed |
NCT02471664 -
Mitral Loop Cerclage(MLC) for Reducing Functional Mitral Regurgitation
|
N/A | |
Active, not recruiting |
NCT02671799 -
Evaluation of the Minimally Invasive VenTouch™ System in the Treatment of Functional Mitral Valve Regurgitation (FMR)
|
N/A | |
Recruiting |
NCT03142152 -
The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With at Least Mild FMR
|
N/A |